 RTT News | Abbott Beats on EPS, Affirms View - Analyst Blog NASDAQ Abbott Labs, along with partner Biogen ( BIIB ), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). Abbott Labs is also working on levodopa-carbidopa intestinal gel (LCIG) for advanced ... Abbott Reports Strong Second Quarter Results |
